405 related articles for article (PubMed ID: 20524813)
21. Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
Greenberg PL
J Natl Compr Canc Netw; 2006 Jan; 4(1):91-6. PubMed ID: 16403408
[TBL] [Abstract][Full Text] [Related]
22. [Post transfusionnal iron overload].
Rose C
Rev Prat; 2006 Dec; 56(19):2141-5. PubMed ID: 17416052
[TBL] [Abstract][Full Text] [Related]
23. Iron chelation therapy in the management of transfusion-related cardiac iron overload.
Fernandes JL
Transfusion; 2012 Oct; 52(10):2256-68. PubMed ID: 22404719
[TBL] [Abstract][Full Text] [Related]
24. Coordination chemistry and biology of chelators for the treatment of iron overload disorders.
Bernhardt PV
Dalton Trans; 2007 Aug; (30):3214-20. PubMed ID: 17893764
[TBL] [Abstract][Full Text] [Related]
25. Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients.
Chan GC; Chan S; Ho PL; Ha SY
Hemoglobin; 2009; 33(5):352-60. PubMed ID: 19814682
[TBL] [Abstract][Full Text] [Related]
26. New chelation therapies and emerging chelating drugs for the treatment of iron overload.
Kontoghiorghes GJ
Expert Opin Emerg Drugs; 2006 Mar; 11(1):1-5. PubMed ID: 16503822
[TBL] [Abstract][Full Text] [Related]
27. Recent developments in iron chelation therapy.
Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
[TBL] [Abstract][Full Text] [Related]
28. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
Voskaridou E; Christoulas D; Terpos E
Br J Haematol; 2011 Sep; 154(5):654-6. PubMed ID: 21615376
[No Abstract] [Full Text] [Related]
29. [Iron and invasive fungal infection].
Álvarez F; Fernández-Ruiz M; Aguado JM
Rev Iberoam Micol; 2013; 30(4):217-25. PubMed ID: 23684655
[TBL] [Abstract][Full Text] [Related]
30. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
[TBL] [Abstract][Full Text] [Related]
31. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators.
Kontoghiorghes GJ; Kolnagou A
Curr Med Chem; 2005; 12(23):2695-709. PubMed ID: 16305466
[TBL] [Abstract][Full Text] [Related]
32. Removal of Fe3+ and Zn2+ from plasma metalloproteins by iron chelating therapeutics depicted with SEC-ICP-AES.
Sooriyaarachchi M; Gailer J
Dalton Trans; 2010 Aug; 39(32):7466-73. PubMed ID: 20623073
[TBL] [Abstract][Full Text] [Related]
33. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
34. The Egyptian experience with oral iron chelators.
El Beshlawy A
Hematology; 2005; 10 Suppl 1():174-5. PubMed ID: 16188665
[TBL] [Abstract][Full Text] [Related]
35. Combined therapy with deferoxamine and deferiprone.
Kattamis A
Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
[TBL] [Abstract][Full Text] [Related]
36. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
37. Therapeutic potential of iron chelators in diseases associated with iron mismanagement.
Weinberg ED
J Pharm Pharmacol; 2006 May; 58(5):575-84. PubMed ID: 16640825
[TBL] [Abstract][Full Text] [Related]
38. Monitoring and treatment of iron overload: state of the art and new approaches.
Porter JB
Semin Hematol; 2005 Apr; 42(2 Suppl 1):S14-8. PubMed ID: 15846580
[No Abstract] [Full Text] [Related]
39. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
Devanur LD; Evans RW; Evans PJ; Hider RC
Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
[TBL] [Abstract][Full Text] [Related]
40. An update on disordered iron metabolism and iron overload.
Ward R
Hematology; 2010 Oct; 15(5):311-7. PubMed ID: 20863426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
